# A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

> **NCT07027163** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Food Hypersensitivity
- Anaphylaxis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07027163
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07027163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07027163, "A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07027163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*